Skip to content

Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT

A Mechanistic, Non-randomised Study to Examine the Uptake of a Specific Radionuclide (61CuATSM) in Carotid Artery Plaque

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01000181
Enrollment
10
Registered
2009-10-22
Start date
2012-10-31
Completion date
Unknown
Last updated
2012-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Atherosclerosis

Brief summary

The build up of plaque in the wall of the artery supplying blood to the brain poses a risk of stroke when the plaques become unstable and fragile. It is important to determine which patients are most at risk so that surgery can be performed. There is evidence that the risk is greatest when these plaques become oxygen deficient (hypoxic). The investigators wish to use PET imaging to identify hypoxic plaque, to help decide whether and when to perform surgery. The investigators have developed radiotracers (imaging agents) for this purpose, and this study is to determine whether they will work in patients.

Interventions

OTHERPET-CT with CuATSM

PET-CT with CuATSM

Sponsors

Guy's and St Thomas' NHS Foundation Trust
CollaboratorOTHER
King's College London
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male/Female patients who are 55yrs or older and for whom carotid endarterectomy is clinically indicated and a decision has been made to perform a carotid endarterectomy. * Normal liver and adequate renal function. Assessed by measuring eGFR (\>50ml/min) and creatinine (\<130μmol/L) * Life expectancy \> 12 weeks * Patients should be able to tolerate head/neck mask as well as lying in the PET-CT scanner

Exclusion criteria

* Abnormal liver and renal function (eGFR \<50ml/min, Creatinine \>130μmol/L) * Patient unwilling to provide written informed consent

Design outcomes

Primary

MeasureTime frame
Uptake of CuATSM in carotid plaqueWithin 30 days of carotid endarterectomy

Secondary

MeasureTime frame
Relationship of CuATSM uptake to plaque histologyWithin 30 days of carotid endarterectomy

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026